Retirement and repurposing of coal-fired power plants are a critical part of the energy transition. This is the core part of programs like Accelerating Coal Transition (ACT) that is being implemented ...
Bringing a single drug to market can take more than a decade and cost billions of dollars, with fewer than one in ten candidates successfully reaching approval. Against this backdrop, generative AI is ...
The multiple condition (MC)-retention model is an uncertainty-aware graph-based neural network that predicts liquid chromatography (LC) retention times across multiple column chem ...
Machine learning has moved past its initial experimental phase. In earlier years, development often focused on creating the ...
In recent years, artificial intelligence has become more accessible than ever before. Powerful libraries, automated platforms ...
Fine-tuning TCAD parameters with real-world feedback from test wafers is essential for quantitatively accurate and predictive results.
Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics and AI-enabled design for RNA therapeutics, today announced the launch of its eCOMPASS™ lab-in-the-loop platform, an ...
Meta's Muse Spark brings multimodal reasoning, health AI, and multi-agent orchestration to users via meta.ai and a private ...
The 2026 season of the Pharma.AI webinar series will showcase the ongoing AI revolution in life sciences, including the ...
The old measurements of leverage, utilization, margin, billing rate, and realization fall short of the new reality.
Meta has introduced Muse Spark, a new AI model developed by Meta Superintelligence Labs. The model is part of a broader Muse ...
As the AI era becomes increasingly shaped by foundation models, the pharmaceutical industry is entering a new phase of opportunity for discovery, design, and decision-making driven by AI for science.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results